Simon Cleary
banner
simoncleary.bsky.social
Simon Cleary
@simoncleary.bsky.social
Research group leader and lecturer in pharmacology at King's College London: kcl.ac.uk/people/simon-cleary
Research interests: pulmonary vascular biology, immunology + developing new therapeutics and microscopy methods.
Reposted by Simon Cleary
Delighted that this study is finally out @embojournal.org. A detailed analysis of how DNGR-1/CLEC9A signals to promote cross-presentation of dead cell-associated antigens yet does not activate dendritic cells.
www.embopress.org/doi/full/10....
DNGR-1 signalling limits dendritic cell activation for optimal antigen cross-presentation | The EMBO Journal
imageimageDNGR-1 (CLEC9A) is a C-type lectin receptor of type-1 conventional dendritic cells (cDC1s) with an important role in cross-presentation of dead cell antigens. This study explores how it equips cDC1s with the ability to cross-present such ...
www.embopress.org
November 3, 2025 at 5:23 PM
Assaying lung samples using spectral flow cytometry? Check out AutoSpectral:
Pre-print alert! And this one really is a must read for anyone that does spectral #flowcytometry. It is a complete, fully-automated spectral unmixing pipeline that reduces error up to 9000-fold.

Want to get a tough sample, like lung, looking like this? Read more!

www.biorxiv.org/content/10.1...
October 28, 2025 at 8:25 AM
Reposted by Simon Cleary
Some good weekend reading. If you thought we’d put the final nails in the coffin of ivermectin as a Covid treatment, you’d be right. But this Perspective goes the extra mile to put the coffin in a lead-lined box and sink it to the bottom of the ocean. 🧵
Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV-2 Antiviral Activities and Lack of Translatability
The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. When ex...
pubs.acs.org
October 12, 2025 at 7:39 PM
Reposted by Simon Cleary
It’s official! 🎉
Our latest paper on the role of the extracellular matrix (ECM) in megakaryopoiesis is out in @elife.bsky.social !
🔗 elifesciences.org/articles/104...
I’m thrilled to share this story with you in a short thread 👇
October 9, 2025 at 7:48 PM
Reposted by Simon Cleary
BioImage analysis friends - King's are recruiting for a full-time, permanent facility position! Come and work with fun microscopes and fun people (and me!) - please share! www.kcl.ac.uk/jobs/126345-...
Bioimage Analysis Specialist | King's College London
www.kcl.ac.uk
September 29, 2025 at 9:48 AM
Reposted by Simon Cleary
For this #FluorescenceFriday, a gorgeous image of an adult mouse kidney labeled with AQP2 and alpha SMA antibodies. AQP2 (green) marks the collecting duct and distal connecting segment while SMA marks the arterial tree. Courtesy of talented postdoc Sarah McLarnon.
September 26, 2025 at 5:51 PM
PhD scholarships available incl. a project with me & Alex Ivetic at King's College London - great programme, facilities, city, colleagues!

Please forward to any suitable undergraduates/MSc students/research assistants.

Info: kcl-mrcdtp.com/project/enha...
Enhancing pulmonary vascular function to heal injured lungs - MRC DTP
To develop improved treatments for inflammatory diseases, we need a better understanding of how pro-inflammatory leukocyte responses resolve. During inflammatory resolution, some recruited leukocytes ...
kcl-mrcdtp.com
September 25, 2025 at 9:44 AM
Reposted by Simon Cleary
Pleased to see this out now in @jem.org 🔬

We characterise the early immune response during M. tuberculosis infection in mouse models and demonstrate a detrimental role for type I interferon activated neutrophils in TB lesions. Thanks to all involved @crick.ac.uk and i3S, Porto.
William J. Branchett, Anne O’Garra @crick.ac.uk et al. reveal that type I signaling early during M. #tuberculosis infection favors #neutrophil swarming and limits CD4+ T cell–#macrophage interactions in #TB lesions, impeding TB disease control. rupress.org/jem/article/...
September 24, 2025 at 6:10 AM
Reposted by Simon Cleary
🚨 New paper in @jclinical-invest.bsky.social!

Kidney lymphatics are a promising target in transplant rejection

🗺️ In rejection, lymphatics expand and adversely remodel

⚡️ Although they have an anti-inflammatory profile, they are attacked by the immune system

www.jci.org/articles/vie...

1/4
September 17, 2025 at 12:32 PM
Reposted by Simon Cleary
New postdoc position available in my lab team! For microscopy of immune cells: please apply or repost or pass on: www.imperial.ac.uk/jobs/search-...
Description
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...
www.imperial.ac.uk
September 10, 2025 at 1:26 PM
PhD opportunity: please contact me if you know someone with a strong interest in respiratory science who would like to apply for a Sir David Jack PhD scholarship.
Details here: www.bps.ac.uk/membership-a...
Course fee waivers possible for outstanding international students.
August 19, 2025 at 11:19 AM
Reposted by Simon Cleary
Thrilled that our paper is in print @science.org!!
*Platelets sequester cell free DNA, including free fetal and tumour-derived DNA*
Tweetorial from @l-cmurphy.bsky.social below. Check out the news feature science.org/content/arti... and terrific editorial from Dennis Lo #platelets_in_the_limelight
August 15, 2025 at 5:37 AM
Reposted by Simon Cleary
Vav-Cre has been transformative for the field, but it is a pain in the a** of a line to work with. Has anyone made a better pan-hematopoietic line? Which one? How specific is it?
August 5, 2025 at 10:49 AM
Reposted by Simon Cleary
Needing some help from all the mouse doctors around! Does anyone know who might keep a B10.D2 mouse colony in the UK (or even mainland Europe)?
August 4, 2025 at 9:21 AM
Reposted by Simon Cleary
New postdoc position in my lab investigating interstitial lung abnormalities (ILA) and mechanisms driving early lung fibrosis @kingscollegelondon.bsky.social @rbandh.bsky.social @gstt-nhs.bsky.social @crick.ac.uk

Closing date 7th August.

Please do consider applying!

my.corehr.com/pls/coreport...
my.corehr.com
July 24, 2025 at 10:15 AM
Enjoyed writing about this important discovery of a 'sluice gate' system enabling lymphatic vessels in the lungs to sense injury and respond by increasing uptake of fluid from the spaces around blood vessels and airways:
rdcu.be/ewCMo

Congrats Chou Chou, Hasina Outtz Reed and colleagues!
July 18, 2025 at 9:32 AM
Reposted by Simon Cleary
Very excited to share our new study comparing the metabolic profile of patient-derived CAR-T cells ex vivo.

CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients: Cell Reports www.cell.com/cell-reports...
CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients
Cook et al. investigate the metabolic profile of DLBCL patient-derived CAR-T cells ex vivo. Comparing Axi-cel (CD28-co-stimulated) and Tisa-cel (4-1BB-co-stimulated) products, they find divergent meta...
www.cell.com
July 17, 2025 at 4:31 PM
Reposted by Simon Cleary
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad.bsky.social lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13)
www.nature.com/articles/s41...
Neutrophils drive vascular occlusion, tumour necrosis and metastasis - Nature
Neutrophils actively induce tumour necrosis, driving vascular occlusion, pleomorphic necrosis and metastasis.
www.nature.com
July 17, 2025 at 11:28 AM
Reposted by Simon Cleary
Spread the word: The European Center for Angioscience @uniheidelberg.bsky.social continues to grow: We have openings for 2 additional Junior Group Leader positions. Get in touch with us if you are ready to start your own lab. See also corresponding ad in @nature.com: www.nature.com/naturecareer...
July 14, 2025 at 10:09 AM
Reposted by Simon Cleary
Our Review just published in Thorax takes a fresh look at how ageing-associated cellular changes lead to epithelial dysfunction and vulnerability, priming the development of pulmonary fibrosis. @jennydickens41.bsky.social @lpearmain.bsky.social

thorax.bmj.com/content/earl...
Epithelial damage and ageing: the perfect storm
Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease of lung parenchymal scarring that is triggered by repeated microinjury to a vulnerable alveolar epithelium. It is increasingly r...
thorax.bmj.com
May 28, 2025 at 11:27 AM
Public access link: rdcu.be/er3Iq
June 27, 2025 at 3:44 PM
Interested in new ways to study interactions between cancers and the immune system? If yes, have a read of this article on mine and Longhui Qiu's recent work, featured in Nature Reviews Cancer's Tools of the Trade series: rdcu.be/er3Iq
June 23, 2025 at 9:52 AM
Reposted by Simon Cleary
For #FluorescenceFriday I'm sharing the fantastic work of postdoc Sarah McLarnon! A follow up to our '23 Development paper where we asked: Does precise vascular patterning matter for function and what happens after ischemic injury? The results were surprising! journals.physiology.org/doi/full/10....
June 20, 2025 at 8:06 PM
Reposted by Simon Cleary
My PhD student isolated some liver endothelial cells and got this brilliant image showing the gradual transition of health EC to full EndMT in a very satisfying circle. #fluorescencefriday #fibrosis
June 13, 2025 at 5:23 PM
Reposted by Simon Cleary
Need help with bioimage analysis? Contact the UK Euro-BioImaging Node to see how we can help!

www.eurobioimaging-access.eu/nodes/uk-node
May 30, 2025 at 3:14 PM